NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING
AGENDA

ROOM: CARLYLE
Delta Chelsea, Toronto, ON
Saturday, May 2nd, 2009
Chair: Dr. Warren Mason
(8:30 a.m. – 12:00 p.m.)

8:30 a.m. WELCOME AND INTRODUCTIONS W. Mason

COMPLETED STUDIES

8:40 a.m. CE.3 – Temozolomide plus RT vs RT for GBM
→ Long-term survivorship update W. Mason

8:50 a.m. IND.170 – A Phase I/II study of GW572016 in GBM
→ Manuscript status B. Thiessen

ACTIVE TRIALS

9:00 a.m. IND.162 – A Phase I/II study of RAD001c plus Temozolomide in GBM W. Mason

9:15 a.m. CE.5 – RT vs Temozolomide for low-grade glioma W. Mason
D. Rheaume

9:45 a.m. CE.6 – RT vs RT plus Temozolomide for elderly GBM N. Laperriere
J. Perry

10:00 a.m. COFFEE BREAK

continued…
FUTURE NCIC PHASE II/III STUDIES

10:15 a.m. CEC.1 – A Phase III trial of Radiotherapy with and without concurrent and adjuvant Temozolomide chemotherapy for 1p/19q non-deleted anaplastic gliomas (CATNON Trial)  
W. Mason

10:30 a.m. CEC.2 – Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial)  
G. Cairncross

IDEAS FOR NEW BRAIN TUMOUR TRIALS

11:00 a.m. NCCTG N0574 - St RT with and without WBRT for 1-3 cerebral metastases  
C. Menard

11:15 a.m. Post-operative radiosurgery to the tumor bed following resection of a single metastasis: A Phase III trial.  
D. Roberge

11:30 a.m. Surgery versus radiosurgery for the treatment of single brain metastases. A prospective randomized trial.  
G. Zadeh

11:45 a.m. Report from the NCIC CTG IND meeting  
W. Mason

12:00 p.m. ADJOURN